Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 10/20 | 0.41 |
| ▸ | USP7 | Q93009 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | CCR6 | P51684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26997909 | 0.97 | PIK3CD (0.40) | PIK3CDUSP7USP30KITHTT | |
| SCHEMBL26997875 | 0.90 | PIK3CD (0.38) | PIK3CDUSP7USP30KITSMN1; SMN2 | |
| SCHEMBL22358154 | 0.89 | PIK3CD (0.38) | PIK3CDUSP7USP30KITHTT | |
| SCHEMBL20676363 | 0.89 | PIK3CD (0.38) | PIK3CDUSP7USP30KITSMN1; SMN2 | |
| SCHEMBL22358038 | 0.88 | PIK3CD (0.41) | PIK3CDUSP7USP30KITHTT | |
| SCHEMBL20116244 | 0.88 | PIK3CD (0.41) | PIK3CDUSP7USP30KITHTT | |
| SCHEMBL20116302 | 0.88 | PIK3CD (0.41) | PIK3CDUSP7USP30KITHTT | |
| SCHEMBL22358410 | 0.88 | TBK1 (0.43) | PIK3CDUSP7USP30KITHTT | |
| SCHEMBL20676662 | 0.88 | PIK3CD (0.40) | PIK3CDUSP7USP30KITHTT | |
| SCHEMBL20676597 | 0.88 | PIK3CD (0.40) | PIK3CDUSP7USP30KITHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | PIK3CD 3927/4885USP7 4265/4885USP30 3526/4885 |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | PIK3CD 3927/4885USP7 4265/4885USP30 3526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.